SCHEMBL6002239

SCHEMBL6002239

C=CCC(C(=O)Cl)c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.50
FFAR2 O15552 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
TGM2 P21980 1/20 0.36
SLC6A2 P23975 2/20 0.35
DRD3 P35462 1/20 0.35
CHRM1 P11229 1/20 0.35
SLC6A4 P31645 1/20 0.35
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264360 1.00 CYP2C19 (0.50) CYP2C19FFAR2SMN1; SMN2HDAC3HDAC4
SCHEMBL4265668 0.84 CYP2C19 (0.71) CYP2C19FFAR2SMN1; SMN2HDAC3HDAC4
SCHEMBL5879290 0.84 CYP2C19 (0.51) CYP2C19FFAR2SMN1; SMN2TGM2HTT
SCHEMBL960592 0.84 CYP2C19 (0.71) CYP2C19FFAR2SMN1; SMN2HDAC3HDAC4
SCHEMBL13946462 0.84 FFAR2 (0.52) CYP2C19FFAR2HDAC4HDAC7HDAC5
SCHEMBL6423644 0.82 CYP2C19 (0.73) CYP2C19FFAR2SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL6423647 0.82 CYP2C19 (0.73) CYP2C19FFAR2SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL13945718 0.81 CYP2C19 (0.49) CYP2C19HDAC4HDAC7HDAC5MEN1
SCHEMBL4257537 0.79 CYP2C19 (0.46) CYP2C19FFAR2SMN1; SMN2HDAC3HDAC4
SCHEMBL28608516 0.78 CYP2C19 (0.57) CYP2C19SMN1; SMN2HTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1497265-B1 COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY GLAXO GROUP LTD (GB) 2009-02-18 EP disclosed
EP-1636221-A2 NEW AZETIDINE COMPOUNDS AstraZeneca AB (SE) 2006-03-22 EP disclosed
EP-1077942-B1 CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS AVENTIS PHARMA INC (US) 2005-01-12 EP disclosed
WO-2004110344-A2 NEW AZETIDINE COMPOUNDS ASTRAZENECA AB (SE) 2004-12-23 WO disclosed
US-6316445-B1 TACHYKININ RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. 2001-11-13 US disclosed
EP-1077942-A1 CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS Aventis Pharmaceuticals Inc. (US) 2001-02-28 EP disclosed
WO-1999059972-A1 CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 1999-11-25 WO disclosed
US-5932571-A Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases HOECHST MARION ROUSSEL, INC. (US) 1999-08-03 US disclosed